

By revenue, UnitedHealth Group is the nation's largest publicly traded managed care company. It operates through two business segments, UnitedHealthcare and Optum. UnitedHealthcare provides healthcare benefits through four membership groups: Employers & Individual, Medicare & Retirement, Community & State, and International. Optum is a health services business that serves payers, care providers, employers, governments, life science companies and consumers. Optum uses advanced data analytics and technology to help optimize the performance of clients. Optum includes OptumRx, which operates a pharmacy benefit management service (PBM).

Analyst's Notes

Analysis by David Young and Katelyn Bayone, July 21, 2016

ARGUS RATING: BUY

- Upgrading to BUY with \$170 target
- We think that UnitedHealth's decision to exit most of the ACA public exchange markets in 2017 will limit its exposure to unprofitable business and lead to stronger EPS growth in 2017.
- We also have a favorable view of the company's Optum businesses, which are growing faster and generating higher margins than its insurance division.
- Based on the company's updated guidance and strong 2Q results, we are raising our adjusted EPS estimates to \$7.85 from \$7.80 for 2016 and to \$9.00 from \$8.70 for 2017.
- UNH trades at 15.8-times our 2017 EPS estimate, slightly below the average of 16.2 for our coverage universe of healthcare services stocks. Given the company's strong growth drivers, we view this as an attractive valuation.

INVESTMENT THESIS


We are upgrading UnitedHealth Group Inc. (NYSE: UNH) to BUY from HOLD and setting a price target of \$170. We think that UnitedHealth's decision to exit most of the ACA public exchange markets in 2017 will limit its exposure to unprofitable business and lead to stronger EPS growth in 2017. We also have a favorable view of the company's Optum businesses, which are growing faster and generating higher margins than its insurance division. In our view, Optum also has greater flexibility to expand organically and through acquisitions as it is not subject to insurance industry regulations. We note that OptumRx, the company's pharmacy benefit management business, saw revenue rise 69% year-over-year in 2Q16.

RECENT DEVELOPMENTS

UNH delivered strong 2Q16 results on July 19. Although the company faces rising utilization and higher costs for its ACA-compliant plans, we expect these pressures to abate

Market Data Pricing reflects previous trading week's closing price.

— 200-Day Moving Average ● Target Price: \$170.00 ● 52 Week High: \$144.48 ● 52 Week Low: \$135.15 ● Closed at \$141.33 on 7/15



Rating	BUY																																																	
EPS (\$)	<table border="1"> <tr> <td>Quarterly</td> <td>1.10</td><td>1.42</td><td>1.63</td><td>1.55</td><td>1.55</td><td>1.73</td><td>1.77</td><td>1.40</td><td>1.81</td><td>1.96</td><td>2.15</td><td>1.93</td><td>2.25</td><td>2.30</td><td>2.30</td><td>2.15</td> </tr> <tr> <td>Annual</td> <td colspan="4">5.70</td><td colspan="4">6.45</td><td colspan="4">7.85 (Estimate)</td><td colspan="4">9.00 (Estimate)</td> </tr> </table>																Quarterly	1.10	1.42	1.63	1.55	1.55	1.73	1.77	1.40	1.81	1.96	2.15	1.93	2.25	2.30	2.30	2.15	Annual	5.70				6.45				7.85 (Estimate)				9.00 (Estimate)			
Quarterly	1.10	1.42	1.63	1.55	1.55	1.73	1.77	1.40	1.81	1.96	2.15	1.93	2.25	2.30	2.30	2.15																																		
Annual	5.70				6.45				7.85 (Estimate)				9.00 (Estimate)																																					
Revenue (\$ in Bil.)	<table border="1"> <tr> <td>Quarterly</td> <td>31.7</td><td>32.6</td><td>32.8</td><td>33.4</td><td>35.8</td><td>36.3</td><td>41.5</td><td>43.6</td><td>44.5</td><td>46.5</td><td>44.4</td><td>46.7</td><td>47.6</td><td>49.7</td><td>47.5</td><td>49.9</td> </tr> <tr> <td>Annual</td> <td colspan="4">130.5</td><td colspan="4">157.1</td><td colspan="4">182.1 (Estimate)</td><td colspan="4">194.8 (Estimate)</td> </tr> </table>																Quarterly	31.7	32.6	32.8	33.4	35.8	36.3	41.5	43.6	44.5	46.5	44.4	46.7	47.6	49.7	47.5	49.9	Annual	130.5				157.1				182.1 (Estimate)				194.8 (Estimate)			
Quarterly	31.7	32.6	32.8	33.4	35.8	36.3	41.5	43.6	44.5	46.5	44.4	46.7	47.6	49.7	47.5	49.9																																		
Annual	130.5				157.1				182.1 (Estimate)				194.8 (Estimate)																																					
FY ends Dec 31	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4																																		
	2014				2015				2016				2017																																					

Argus Recommendations

Twelve Month Rating	SELL	HOLD	BUY
Five Year Rating	SELL	HOLD	BUY
Sector Rating	Under Weight	Market Weight	Over Weight

Argus assigns a 12-month BUY, HOLD, or SELL rating to each stock under coverage.

- BUY-rated stocks are expected to outperform the market (the benchmark S&P 500 Index) on a risk-adjusted basis over the next year.
- HOLD-rated stocks are expected to perform in line with the market.
- SELL-rated stocks are expected to underperform the market on a risk-adjusted basis.

The distribution of ratings across Argus' entire company universe is: 47% Buy, 47% Hold, 6% Sell.

Key Statistics

Key Statistics pricing data reflects previous trading day's closing price. Other applicable data are trailing 12-months unless otherwise specified

Market Overview

Price	\$142.87
Target Price	\$170.00
52 Week Price Range	\$95.00 to \$144.48
Shares Outstanding	950.80 Million
Dividend	\$2.50

Sector Overview

Sector	Healthcare
Sector Rating	MARKET WEIGHT
Total % of S&P 500 Market Cap.	14.00%

Financial Strength

Financial Strength Rating	MEDIUM-HIGH
Debt/Capital Ratio	47.5%
Return on Equity	20.4%
Net Margin	3.5%
Payout Ratio	0.30
Current Ratio	0.74
Revenue	\$176.10 Billion
After-Tax Income	\$6.18 Billion

Valuation

Current FY P/E	15.87
Prior FY P/E	18.20
Price/Sales	0.77
Price/Book	3.74
Book Value/Share	\$38.16
Market Capitalization	\$135.84 Billion

Forecasted Growth

1 Year EPS Growth Forecast	21.71%
5 Year EPS Growth Forecast	15.00%
1 Year Dividend Growth Forecast	26.74%

Risk

Beta	0.91
Institutional Ownership	87.85%

Analyst's Notes...Continued

as it exits the public exchange markets in all but three states in 2017.

Second-quarter adjusted EPS came to \$1.96, up from \$1.73 a year earlier and above the consensus forecast of \$1.89. GAAP net income rose to \$1.75 billion or \$1.81 per share from \$1.58 billion or \$1.73 per share in 2Q15. Revenue grew 28% to \$46.5 billion. Both UnitedHealthcare (insurance) and Optum (services, health IT, and pharmacy benefit management) recorded strong revenue growth.

Revenue in the insurance business rose 14% to \$37.6 billion, though the segment margin fell 90 basis points to 5.2%. This was largely due to wider losses from ACA-compliant plans underwritten by UNH. The consolidated medical loss ratio was 82.0%, up 30 basis points. With the exchange plans accounting for \$200 million in losses over and above previous projections, the MLR rose a net 50 basis points. Excluding the exchange plan losses, however, the MLR declined (improved). Management noted that hospital admissions of members continue to trend lower, though the utilization of specialty pharma, and ER and outpatient services has been trending higher. Overall, the company said that its commercial medical trend remains consistent with its original projection of 6.0%, plus/minus 50 basis points.

In the Optum segment, which includes three separate businesses (OptumHealth, OptumInsight and OptumRx), revenue grew 52% to \$20.6 billion, though the segment margin declined 30 basis points to 6.1%. This reflected strong membership growth at

OptumRx pharmacy services, which has lower margins than the other Optum businesses. On the positive side, OptumRx revenue rose 69% to \$15.1 billion, driven by acquisitions and organic growth.

EARNINGS & GROWTH ANALYSIS

UNH has raised its earnings guidance for 2016, and now expects adjusted EPS of \$7.80-\$7.95, up from a prior \$7.75-\$7.90. It reaffirmed its revenue forecast of \$182 billion.

Based on the updated guidance and strong 2Q results, we are raising our adjusted EPS estimates to \$7.85 from \$7.80 for 2016 and to \$9.00 from \$8.70 for 2017. We expect that UNH's exit from most of the public exchange markets will end the losses experienced in 2016 and lead to stronger earnings growth in 2017.

RISKS

UnitedHealth and other insurers face higher costs related to compliance with the Affordable Care Act. In response, UNH is raising prices and has decided to withdraw from the public exchanges in all but three states.

COMPANY DESCRIPTION

By revenue, UnitedHealth Group is the nation's largest publicly traded managed care company. It operates through two business segments, UnitedHealthcare and Optum. UnitedHealthcare provides healthcare benefits through four membership groups: Employers & Individual, Medicare & Retirement, Community &

Growth & Valuation Analysis
GROWTH ANALYSIS

(\$ in Millions, except per share data)

	2012	2013	2014	2015	2016
Revenue	103,712	113,676	123,857	134,522	165,878
COGS	77,966	85,427	92,978	99,730	127,484
Gross Profit	25,746	28,249	30,879	34,792	38,394
SG&A	16,036	17,824	19,942	22,436	25,236
R&D	—	—	—	—	—
Operating Income	8,560	9,076	9,538	10,860	11,341
Interest Expense	535	662	690	608	899
Pretax Income	8,025	8,414	8,848	10,252	10,442
Income Taxes	2,841	3,036	3,316	4,319	4,360
Tax Rate (%)	36	36	42	43	—
Net Income	5,184	5,330	5,532	5,933	6,011
Diluted Shares Outstanding	1,077	1,038	1,015	979	967
EPS	4.82	5.13	5.44	6.06	6.22
Dividend	0.65	0.85	1.12	1.50	2.00

GROWTH RATES (%)

	2012	2013	2014	2015	2016
Revenue	8.6	10.7	6.5	20.6	—
Operating Income	9.3	4.0	6.8	7.3	—
Net Income	7.5	1.8	-0.1	3.5	—
EPS	11.6	4.2	3.6	5.4	—
Dividend	30.6	31.6	33.5	33.5	—
Sustainable Growth Rate	15.8	14.2	13.1	13.4	12.2

VALUATION ANALYSIS

	2012	2013	2014	2015	2016
Price: High	\$60.75	\$75.88	\$104.00	\$126.21	—
Price: Low	\$49.82	\$51.36	\$69.57	\$95.00	—
Price/Sales: High-Low	0.6 - 0.5	0.7 - 0.5	0.9 - 0.6	0.9 - 0.7	— - —
P/E: High-Low	12.6 - 10.3	14.8 - 10.0	19.1 - 12.8	20.8 - 15.7	— - —
Price/Cash Flow: High-Low	8.9 - 7.3	10.3 - 6.9	15.5 - 10.4	14.1 - 10.6	— - —

Financial & Risk Analysis
FINANCIAL STRENGTH

	2014	2015	2016
Cash (\$ in Millions)	—	—	—
Working Capital (\$ in Millions)	—	—	—
Current Ratio	0.77	0.74	—
LT Debt/Equity Ratio (%)	49.3	75.3	—
Total Debt/Equity Ratio (%)	53.6	94.9	—

RATIOS (%)

Gross Profit Margin	25.3	23.6	—
Operating Margin	7.9	7.0	—
Net Margin	4.3	3.7	—
Return On Assets	6.7	5.9	—
Return On Equity	17.4	17.5	—

RISK ANALYSIS

Cash Cycle (days)	—	—	—
Cash Flow/Cap Ex	—	—	—
Oper. Income/Int. Exp. (ratio)	16.6	14.0	—
Payout Ratio	—	—	—

The data contained on this page of this report has been provided by Morningstar, Inc. (© 2016 Morningstar, Inc. All Rights Reserved). This data (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. This data is set forth herein for historical reference only and is not necessarily used in Argus' analysis of the stock set forth on this page of this report or any other stock or other security. All earnings figures are in GAAP.

Analyst's Notes...Continued

State, and International. Optum is a health services business that serves payers, care providers, employers, governments, life science companies and consumers. Optum uses advanced data analytics and technology to help optimize the performance of clients. Optum includes OptumRx, which operates a pharmacy benefit management service (PBM).

INDUSTRY

Our recommended weighting on the Healthcare sector is Market-Weight. We lowered our weighting from Over-Weight amid signs that a new Democratic president would attempt to impose drug price caps, and that a Republican president would continue attempts to dismantle the Affordable Care Act. The Healthcare sector accounts for 14.7% of the S&P 500, and includes companies in the pharmaceuticals, hospital, medical devices, and insurance industries.

The Healthcare sector has benefited from its perceived insulation from economic turbulence. In addition, many Healthcare stocks have benefited as the pool of people with insurance expands under the ACA.

The sector outperformed in 2015, with a gain of 5.2%, and in 2014, with a gain of 23.3%. It is underperforming thus far in 2016, with a gain of 3.3%.

Fundamentals for Healthcare stocks appear reasonable. According to our model, the projected P/E ratio on 2017 EPS is 14.5, below the market multiple of 15.4. The sector's debt ratios

are low, with an average debt-to-cap ratio of 35%, below the market average. Yields of about 1.7% are below the average for the S&P 500, but still attractive for some Big Pharma companies.

VALUATION


UNH trades at 15.8-times our 2017 EPS estimate, slightly below the average of 16.2 for our coverage universe of healthcare services stocks. Given the company's strong growth drivers, we think this is an attractive valuation. We are raising our rating to BUY with a price target of \$170.

On July 21, BUY-rated UNH closed at \$142.87, down \$0.15.

Peer & Industry Analysis






The graphics in this section are designed to allow investors to compare UNH versus its industry peers, the broader sector, and the market as a whole, as defined by the Argus Universe of Coverage.

- The scatterplot shows how UNH stacks up versus its peers on two key characteristics: long-term growth and value. In general, companies in the lower left-hand corner are more value-oriented, while those in the upper right-hand corner are more growth-oriented.
- The table builds on the scatterplot by displaying more financial information.
- The bar charts on the right take the analysis two steps further, by broadening the comparison groups into the sector level and the market as a whole. This tool is designed to help investors understand how UNH might fit into or modify a diversified portfolio.



Ticker	Company	Market Cap (\$ in Millions)	5-yr Growth Rate (%)	Current FY P/E	Net Margin (%)	1-yr EPS Growth (%)	Argus Rating
UNH	Unitedhealth Group Inc	135,841	15.0	18.2	3.5	14.6	BUY
CELG	Celgene Corp	83,231	22.0	19.0	17.4	24.8	BUY
TMO	Thermo Fisher Scientific Inc	61,467	10.0	19.2	11.5	8.2	BUY
ESRX	Express Scripts Holding Co	49,711	15.0	12.4	2.5	6.0	HOLD
MCK	McKesson Corp	44,349	10.0	14.6	1.2	5.9	HOLD
AET	Aetna Inc	41,476	15.0	14.5	3.8	11.0	BUY
CI	Cigna Corp	28,242	10.0	14.3	5.9	—	HOLD
CAH	Cardinal Health Inc	26,916	15.0	15.6	1.2	12.3	BUY
HUM	Humana Inc	25,564	11.0	19.5	2.0	9.1	HOLD
Peer Average		55,200	13.7	16.4	5.4	11.5	

P/E

Price/Sales

Price/Book

PEG

5 Year Growth

Debt/Capital


About Argus

Argus Research, founded by Economist Harold Dorsey in 1934, has built a top-down, fundamental system that is used by Argus analysts. This six-point system includes Industry Analysis, Growth Analysis, Financial Strength Analysis, Management Assessment, Risk Analysis and Valuation Analysis.

Utilizing forecasts from Argus' Economist, the Industry Analysis identifies industries expected to perform well over the next one-to-two years.

The Growth Analysis generates proprietary estimates for companies under coverage.

In the Financial Strength Analysis, analysts study ratios to understand profitability, liquidity and capital structure.

During the Management Assessment, analysts meet with and familiarize themselves with the processes of corporate management teams.

Quantitative trends and qualitative threats are assessed under the Risk Analysis.

And finally, Argus' Valuation Analysis model integrates a historical ratio matrix, discounted cash flow modeling, and peer comparison.

THE ARGUS RESEARCH RATING SYSTEM

Argus uses three ratings for stocks: BUY, HOLD, and SELL. Stocks are rated relative to a benchmark, the S&P 500.

- A BUY-rated stock is expected to outperform the S&P 500 on a risk-adjusted basis over a 12-month period. To make this determination, Argus Analysts set target prices, use beta as the measure of risk, and compare expected risk-adjusted stock returns to the S&P 500 forecasts set by the Argus Market Strategist.
- A HOLD-rated stock is expected to perform in line with the S&P 500.
- A SELL-rated stock is expected to underperform the S&P 500.

Argus Research Disclaimer

Argus Research is an independent investment research provider and is not a member of the FINRA or the SIPC. Argus Research is not a registered broker dealer and does not have investment banking operations. The Argus trademark, service mark and logo are the intellectual property of Argus Group Inc. The information contained in this research report is produced and copyrighted by Argus, and any unauthorized use, duplication, redistribution or disclosure is prohibited by law and can result in prosecution. The content of this report may be derived from Argus research reports, notes, or analyses. The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Argus makes no representation as to their timeliness, accuracy or completeness or for their fitness for any particular purpose. This report is not an offer to sell or a solicitation of an offer to buy any security. The information and material presented in this report are for general information only and do not specifically address individual investment objectives, financial situations or the particular needs of any specific person who may receive this report. Investing in any security or investment strategies discussed may not be suitable for you and it is recommended that you consult an independent investment advisor. Nothing in this report constitutes individual investment, legal or tax advice. Argus may issue or may have issued other reports that are inconsistent with or may reach different conclusions than those represented in this report, and all opinions are reflective of judgments made on the original date of publication. Argus is under no obligation to ensure that other reports are brought to the attention of any recipient of this report. Argus shall accept no liability for any loss arising from the use of this report, nor shall Argus treat all recipients of this report as customers simply by virtue of their receipt of this material. Investments involve risk and an investor may incur either profits or losses. Past performance should not be taken as an indication or guarantee of future performance. Argus has provided independent research since 1934. Argus officers, employees, agents and/or affiliates may have positions in stocks discussed in this report. No Argus officers, employees, agents and/or affiliates may serve as officers or directors of covered companies, or may own more than one percent of a covered company's stock.

Morningstar Disclaimer

© 2016 Morningstar, Inc. All Rights Reserved. Certain financial information included in this report: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.